About CRISPR Therapeutics AG
https://www.crisprtx.comCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA.
CEO
Samarth Kulkarni
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 147
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Needham
Buy
Chardan Capital
Buy
Citigroup
Buy
B of A Securities
Buy
HC Wainwright & Co.
Buy
Truist Securities
Buy
Grade Summary
Showing Top 6 of 18
Price Target
Institutional Ownership
ARK INVESTMENT MANAGEMENT LLC
Shares:9.79M
Value:$556.78M
BLACKROCK, INC.
Shares:7.05M
Value:$401.08M
CAPITAL INTERNATIONAL INVESTORS
Shares:5.65M
Value:$321.39M
Summary
Showing Top 3 of 547
About CRISPR Therapeutics AG
https://www.crisprtx.comCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $889K ▲ | $68.25M ▼ | $-106.44M ▲ | -11.97K% ▼ | $-1.17 ▲ | $-101.39M ▲ |
| Q2-2025 | $0 ▼ | $184.17M ▲ | $-208.55M ▼ | 0% ▲ | $-2.4 ▼ | $-224.68M ▼ |
| Q1-2025 | $865K ▼ | $91.78M ▼ | $-136M ▼ | -15.72K% ▼ | $-1.58 ▼ | $-143.69M ▼ |
| Q4-2024 | $35M ▲ | $99.59M ▲ | $-37.31M ▲ | -106.6% ▼ | $-0.44 ▲ | $-59.75M ▲ |
| Q3-2024 | $0 | $98.98M | $-85.94M | 0% | $-1.01 | $-105.39M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.92B ▲ | $2.25B ▲ | $329.33M ▲ | $1.92B ▲ |
| Q2-2025 | $1.72B ▼ | $2.03B ▼ | $318.59M ▼ | $1.71B ▼ |
| Q1-2025 | $1.86B ▼ | $2.17B ▼ | $336.94M ▲ | $1.83B ▼ |
| Q4-2024 | $1.9B ▼ | $2.24B ▼ | $309.95M ▼ | $1.93B ▼ |
| Q3-2024 | $1.94B | $2.26B | $316.47M | $1.94B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-106.44M ▲ | $-84.63M ▲ | $-119.23M ▼ | $296.77M ▲ | $92.88M ▲ | $-84.71M ▲ |
| Q2-2025 | $-208.55M ▼ | $-113.88M ▼ | $69.98M ▲ | $2.26M ▼ | $-41.56M ▲ | $-114M ▼ |
| Q1-2025 | $-136M ▼ | $-53.95M ▼ | $-19.75M ▼ | $10.59M ▼ | $-63.07M ▼ | $-54.15M ▼ |
| Q4-2024 | $-37.31M ▲ | $-50.03M ▲ | $105.83M ▲ | $16.88M ▲ | $72.59M ▲ | $-50.28M ▲ |
| Q3-2024 | $-85.94M | $-106.91M | $-161.6M | $9.64M | $-258.8M | $-107.13M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Samarth Kulkarni
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 147
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Needham
Buy
Chardan Capital
Buy
Citigroup
Buy
B of A Securities
Buy
HC Wainwright & Co.
Buy
Truist Securities
Buy
Grade Summary
Showing Top 6 of 18
Price Target
Institutional Ownership
ARK INVESTMENT MANAGEMENT LLC
Shares:9.79M
Value:$556.78M
BLACKROCK, INC.
Shares:7.05M
Value:$401.08M
CAPITAL INTERNATIONAL INVESTORS
Shares:5.65M
Value:$321.39M
Summary
Showing Top 3 of 547